News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors
CAMBRIDGE, Mass. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C. Martin , Ph.D., to its Board of Directors, effective today. Dr.
View HTML
Toggle Summary Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday,
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Dec. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under
View HTML
Toggle Summary Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001
– Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States – – At closing, Sarepta will receive an upfront payment of $1.15 billion , comprising $750 million in cash and $400 million in Sarepta stock, priced at $158.59 per share of common stock –   –
View HTML
Toggle Summary Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing
CAMBRIDGE, Mass. , Dec. 13, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has entered into an agreement with funds managed by Pharmakon Advisors, LP , that provides Sarepta with up to $500
View HTML
Toggle Summary Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
-- VYONDYS 53 is Sarepta’s second RNA exon-skipping treatment for DMD approved in the U.S. -- -- Commercial distribution of VYONDYS 53 in the U.S. will commence immediately -- -- Information for patients and clinicians is available at www.SareptAssist.com --  CAMBRIDGE, Mass. , Dec.
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under
View HTML
Toggle Summary Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies
-- Agreement leverages StrideBio’s novel, industry-leading, structure-driven capsid engineering platform and expands Sarepta’s early stage gene therapy pipeline – -- Sarepta granted an exclusive license to four CNS targets, on which StrideBio will lead early research and development inclusive of
View HTML
Toggle Summary Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2019. “EXONDYS 51® (eteplirsen) enjoyed another strong quarter, with third quarter
View HTML
Toggle Summary Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Credit Suisse 28 th Annual Healthcare Conference on Tuesday, Nov.
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.